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The fusion protein SS18-SSX1 
employs core Wnt pathway 
transcription factors to induce a 
partial Wnt signature in synovial 
sarcoma
Luisa Cironi1, Tanja Petricevic1, Victor Fernandes  Vieira1, Paolo Provero2, Carlo Fusco1, 
Sandrine Cornaz1, Giulia Fregni1, Igor Letovanec1, Michel Aguet3 & Ivan Stamenkovic1
Expression of the SS18/SYT-SSX fusion protein is believed to underlie the pathogenesis of synovial 
sarcoma (SS). Recent evidence suggests that deregulation of the Wnt pathway may play an important 
role in SS but the mechanisms whereby SS18-SSX might affect Wnt signaling remain to be elucidated. 
Here, we show that SS18/SSX tightly regulates the elevated expression of the key Wnt target AXIN2 in 
primary SS. SS18-SSX is shown to interact with TCF/LEF, TLE and HDAC but not β-catenin in vivo and 
to induce Wnt target gene expression by forming a complex containing promoter-bound TCF/LEF and 
HDAC but lacking β-catenin. Our observations provide a tumor-specific mechanistic basis for Wnt target 
gene induction in SS that can occur in the absence of Wnt ligand stimulation.
Synovial sarcoma (SS) is an aggressive soft tissue malignancy predominantly of young adults that can develop 
in virtually any organ and is believed to originate from pluripotent mesenchymal cells1,2. More than 90% of SS 
are associated with the chromosomal translocation t(X;18)(p11;q11) that results in fusion of the ubiquitously 
expressed SYT/SS18 gene to one of the SSX family members, most frequently SSX1 and 23. Neither SS18 nor SSX 
proteins have DNA binding domains but both possess protein-protein interaction motifs that mediate association 
with transcriptional regulators and chromatin remodeling complexes4–6.
Mounting evidence suggests that the Wnt pathway is strongly implicated in SS pathogenesis7–9. The Wnt family 
of secreted proteins fulfills key evolutionarily conserved functions in normal development and adult tissue main-
tenance10–13 and its deregulation by alteration of expression or mutation of its key components including β− cat-
enin, adenomateous polyposis coli (APC) and AXIN, is associated with development and progression of diverse 
cancer types13–18. Expression of SS18/SSX in HEK293 cells has been suggested to activate Wnt- β -catenin sign-
aling. Studies on the MYF5-CRE SS18/SSX2 transgenic model of SS found that SS18-SSX2 aberrantly activates 
Wnt/β -catenin signaling and that genetic deletion of β -catenin blocks tumor formation19. They also suggested that 
SS18-SSX causes nuclear β -catenin accumulation, possibly by inducing autocrine signaling through its aberrant 
transcriptional effects. In contrast, introduction of SS18/SSX into NIH3T3 cells induced Wnt ligand-independent 
accumulation of β -catenin in the nucleus7, suggesting an alternative mechanism of SS18-SSX-dependent dereg-
ulation of Wnt. Despite elevated expression of several Wnt target genes, particularly AXIN2, nuclear localization 
of ß-catenin is seen in only 30–60% of SS20–22 and genetic screens23,24 revealed low incidence of β− catenin, APC, 
AXIN1 and AXIN2 mutations25. The molecular mechanisms whereby SS18-SSX may alter Wnt signaling and 
target gene expression thus remain to be fully elucidated.
Engagement of cell surface receptors by Wnt ligands triggers intracellular signaling that can activate the canon-
ical Wnt/β -catenin and a variety of non-canonical Wnt pathways12. A direct consequence of Wnt ligand-receptor 
interaction is the inactivation of a complex composed of APC, axin and glycogen synthase kinase (GSK3)β , which 
1Institute of Pathology University of Lausanne and CHUV Lausanne, Switzerland. 2Center for Translational Genomics 
and Bioinformatics San Raffaele Scientific Institute Milan, Italy. 3Swiss Institute for Experimental Cancer Research 
Ecole Polytechnique Fédérale de Lausanne Lausanne, Switzerland. Correspondence and requests for materials 
should be addressed to I.S. (email: Ivan.Stamenkovic@chuv.ch)
Received: 01 July 2015
accepted: 08 February 2016
Published: 24 February 2016
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 6:22113 | DOI: 10.1038/srep22113
in the absence of Wnt ligands targets β -catenin for proteosomal degradation12. Engagement of receptors by Wnt 
ligands causes β -catenin to accumulate in the cytoplasm, translocate to the nucleus and bind to the T cell-specific 
factor/lymphoid enhancer-binding factor (TCF/LEF) complex to modulate TCF/LEF-dependent transcription of 
target genes. In the absence of β -catenin, TCF/LEF family members form a repressor complex with co-repressor 
partners, primarily transducin-like enhancer of split 1 (TLE1)26 and histone deacetylase (HDAC)27,28. Induction 
of Wnt target gene expression is therefore proposed to occur in at least two steps27: nuclear β -catenin first engages 
in promoter de-repression by disrupting the repressor complex composed of HDAC, TLE and TCF/LEF; as its 
level continues to rise in response to Wnt ligands, β -catenin associates with TCF/LEF1 to induce transcriptional 
activation. TCF/LEF-1 may therefore transition from transcriptional repressors when bound to TLE and HDAC 
to transcriptional activators when dissociated from TLE/HDAC and bound to β -catenin27.
In the present work we addressed possible functionally relevant interactions between SS18-SSX and nuclear 
components of the Wnt signaling pathway in mouse C3H10T1/2 pluripotent mesenchymal cells. We show that 
in the absence of exogenous soluble Wnt ligands, SS18-SSX1 forms complexes with TCF/LEF, TLE1 and HDAC 
that exclude β -catenin and induces a partial Wnt signature that includes elevated expression of AXIN2 in addition 
to several other Wnt target genes. Because AXIN2 faithfully reflects Wnt pathway activation in neither tissue 
nor context-dependent manner and is among the most strongly upregulated Wnt target genes in SS9,29,30, we 
interrogated the functional relationship between SS18-SSX, HDAC and TCF/LEF at the AXIN2 promoter. Our 
observations suggest that SS18-SSX participates in de-repression of AXIN2 expression by inhibiting HDAC and 
augmenting Histone H3K9 acetylation at its promoter and propose a mechanistic basis for SS18-SSX-mediated 
deregulation of Wnt target gene expression in permissive cells.
Results
AXIN2 transcripts in primary SS correlate with SS18-SSX expression levels. Analysis, by real time 
PCR, of AXIN2 expression in 10 synovial sarcoma specimens revealed one to three orders of magnitude higher 
levels of AXIN2 mRNA than in populations of freshly isolated primary candidate cells of origin of SS, including 
human mesenchymal stem cells (MSCs), myoblasts and satellite cells (Fig. 1A upper panel). The same analy-
sis of two additional freshly isolated SS (SS11 from the lung and SS12 from the lower leg) yielded comparable 
results (Fig. 1A, lower panel). To verify that elevated AXIN2 message in SS is a direct consequence of SS18-SSX 
expression, we depleted of the fusion protein two SS cell lines (HS-SYII and FUJI) and cells from the two fresh 
surgical SS samples. We used either a pool of siRNAs directed against the 5′ region of human SS18/SYT or a pool 
of two shRNAs in the lentiviral pLVShRNAmir plasmid targeting the SS18-SSX breakpoint (ShSS18-SSXbp) or 
an ShRNA already described by Kadoch and Crabtree31. AllStars siRNA, empty pLVShRNAmir vector or empty 
pLKO.1 vector provided negative controls. As assessed by qPCR, SS18-SSX1 and AXIN2 mRNA were depleted 
respectively by 48% and 40% in SS11, 43% and 54% in SS12, 75% and 50% in HS-SYII, 55% and 34% in FUJI cells 
(Fig. 1B), consistent with tight association between AXIN2 transcripts and SS18-SSX expression in SS.
SS18-SSX1 regulates AXIN2 promoter activity in cell context specific manner. To address the 
mechanism whereby SS18-SSX deregulates Wnt signaling in primary cells, we sought to identify mesenchymal 
cells that are permissive for robust SS18-SSX-mediated induction of AXIN2 expression. We therefore introduced 
HA- or V5-tagged SS18-SSX1 into a range of cell types, including primary human MSC from both bone mar-
row and peripheral tissues, freshly isolated human myoblasts and satellite cells, primary bone marrow-derived 
mouse mesenchymal progenitor cells (MPC), and pluripotent mouse mesenchymal C3H10T1/2 cells that display 
MSC type plasticity32,33 (Fig. 1C). Comparable expression of SS18-SSX1, as assessed by Western blot analysis, was 
achieved in all of the selected cell types (not shown) but only C3H10T1/2SS18-SSX1 cells displayed roughly 100 fold 
induction of AXIN2 that mimicked the expression observed in primary SS samples (Fig. 1A,C). The effect did not 
differ significantly whether SS18-SSX was tagged with C-terminal V5 or N-terminal HA (data not shown) and 
required expression of the entire fusion protein as neither wt nor truncated SS18/SYT over-expression induced 
AXIN2 expression (Fig. S1).
Further evidence that SS18-SSX regulates AXIN2 transcript levels was provided by removing the provi-
rus genome (flanked by two LOXp sites) through the expression of the CRE recombinase. Q-PCR analysis of 
SS18-SSX and AXIN2 revealed a very strong reduction of both transcripts in C3H10T1/2SS18-SSX1-V5 cells express-
ing the CRE recombinase (Fig. 1D,a,b) and SS18-SSX protein was reduced to a level below the detection of 
Western blot (Fig. 1D,c).
To determine whether SS18-SSX1 affects AXIN2 promoter activity, an AXIN2 promoter-driven lucif-
erase reporter (from –2954 to + 2688) (Gene ID: 12006, 1st ATG = +1) was constructed in the PGL3 vector. 
C3H10T1/2pLIVc, C3H10T1/2SS18-SSX1-V5 and C3H10T1/2SS18-SSX1-HA cells were transiently transfected with either the 
reporter or an empty PGL3 plasmid. STO mouse fibroblasts (where induction of AXIN2 following expression of 
SS18-SSX1 was not observed) transfected with the same constructs provided a negative control. Luciferase activ-
ity was measured 48 hours after transfection and normalized to that of renilla as an internal control. C3H10T1/2wt 
and C3H10T1/2pLIVc cells as well as STOpLIVc and STOSS18-SSX-V5 containing the reporter plasmid displayed no sig-
nificant increase in luciferase activity compared to their PGL3 containing counterparts. By contrast, robust induc-
tion of luciferase activity was observed in both C3H10T1/2SS18-SSX1-V5 and C3H10T1/2SS18-SSX1-HA cells (Fig. 1E).
SS18-SSX expression induces a partial Wnt signature in C3H10T1/2 cells. We next compared 
transcriptome changes in C3H10T1/2SS18-SSX1-V5 and C3H10T1/2pLIVc cells on Affymetrix arrays and analyzed >2 
fold differentially expressed probesets (Tables S1 and S2). Comparison of lists of both repressed and induced 
genes in C3H10T1/2SS18-SSX1 cells to existing databases revealed a significant overlap with SS signatures reported 
by Francis et al.30 (p = 10−6 for repressed and 10−10 for induced genes) and Baird et al.34 (p = 10−6 for induced 
genes). Thus, SS18/SSX1 induces a SS-related transcriptome in C3H10T1/2 cells (Table S3).
www.nature.com/scientificreports/
3Scientific RepoRts | 6:22113 | DOI: 10.1038/srep22113
Over-representation of a limited selection of KEGG pathway terms for induced genes (complete lists are found 
on the GEO website) in C3H10T1/2SS18-SSX1 cells included Wnt signaling pathway (KEGG id 04310, p = 0.0011). 
Particularly significant was over-representation of Wnt signaling-associated and Wnt target genes among 
transcripts induced by SS18-SSX1 in C3H10T1/2 cells (p ~ 10−13, Table S4). To compare SS18-SSX- and Wnt 
Figure 1. SS18-SSX regulates mRNA levels in cell context-specific manner. (A) Q -PCR analysis of 
AXIN2 in primary human SS, satellite cells, myoblasts and MSC. (B) Q-PCR analysis of AXIN2 and SS18-SSX 
(indicated) after SS18-SSX depletion in SS cells and SS cell lines. (C,D) Q-PCR analysis of AXIN2 transcripts 
and SS18-SSX (indicated) in C3H10T1/2 cells. In (C) cells were infected with V5-tagged SS18-SSX1 (SS-V5) 
or empty pLIVc vector and selected for 10 days in 1 μg/ml puromycin. In (D) selected C3H10T1/2pLIVc and 
C3H10T1/2SS18-SSX1-V5 cells were infected with LV-CRE pLKO.1 or an empty pLKO.1 vector and harvested 
96 hours later. Protein expression and knockdown were assessed by Western blot analysis (inset in (C) and lowest 
panel in D) using mouse anti-V5 and HRP-conjugated goat anti-mouse IgG. Monoclonal mouse anti-tubulin 
antibody provided the loading control. Q-PCR results are representative of two (B) or three (D) independent 
experiments. Bar represents the SD of triplicate PCRs; in B the significance (indicated by asterisks) of SS18-
SSX and AXIN2 repression was p = 0.014 and p = 0.022, respectively, for SS11, p = 0.0130 and p = 1.03E-5 
for SS12, p = 0.000738 and 6.74E-5 for HS-SYII and p = 0.000297 and 0.0103 for FUJI. (E) The effect of SS18-
SSX1 expression on mouse AXIN2 promoter activity was measured in STO cells stably expressing V5-tagged 
SS18-SSX1 protein or empty pLIVc, and in wild type C3H10T1/2, C3H10T1/2pLIVc, C3H10T1/2SS18-SSX1-V5 and 
C3H10T1/2SS18-SSX1-HA cells. The ratio of firefly to renilla luciferase activity is reported. Results are representative 
of three independent experiments. Error bars represent the SD of triplicate tests.
www.nature.com/scientificreports/
4Scientific RepoRts | 6:22113 | DOI: 10.1038/srep22113
ligand-induced gene signatures in C3H10T1/2, we analyzed transcriptome changes in C3H10T1/2 cells subjected 
to 0.1 μM recombinant Wnt3a stimulation for 24 hrs. Using three biological replicates at a 10% FDR, we iden-
tified 127 up- and 148 down-regulated probes. A highly significant overlap was found with genes differentially 
expressed upon introduction of SS18-SSX with p values of 3.54E-22 and 1.77E-9 for induced and repressed genes, 
respectively (Table S4 and S5) indicating that SS18-SSX induces a partial Wnt signature in C3H10T1/2 cells. Wnt 
target genes were not found among SS18-SSX1-induced or repressed transcripts in STO cells, underscoring con-
text specificity of the SS18-SSX-induced Wnt signature (Table S6).
In the absence of exogenous Wnt ligands, SS18-SSX1-mediated AXIN2 induction does not 
require the LEF-1/β-catenin complex. AXIN2 is a direct target of a complex that includes TCF/LEF 
transcription factors and β -catenin29. To determine whether the β -catenin –TCF/LEF complex is implicated in 
AXIN2 induction by SS18-SSX1, we expressed a dominant negative (ΔN) mouse LEF-1 mutant, which lacks the 
β -catenin binding domain but retains intact DNA binding activity35, in C3H10T1/2pLIVc and C3H10T1/2SS18-SSX1-V5 
cells. Lentiviral infection efficiency was assessed by red fluorescent protein (RFP) signal intensity co-expressed 
by the same bicistronic vector (Fig. 2A upper panel), and AXIN2 mRNA levels were determined by qRT-PCR 
(Fig. 2A lower panel). A < 10% decrease in AXIN2 mRNA levels was observed in the presence of ΔN LEF-1 in 
Figure 2. SS18-SSX1-dependent AXIN2 promoter activity does not involve the LEF-1 β–catenin activation 
complex. (A) (upper panel) Fluorescence microscopy images of C3H10T1/2pLIVc (a) and C3H10T1/2SS18-SSX1-V5 
(b) cells infected with a lentiviral vector expressing both ΔNLEF-1 and RFP, 200X magnification; (lower panel) 
AXIN2 message was assessed by Q-PCR after 24 hr stimulation with 100 ng/ml recombinant Wnt3a or PBS. (B) 
mAXIN2 promoter activity in C3H10T1/2SS18-SSX1-V5 infected with ΔNLEF-1 or control vector. The ratio of firefly 
to renilla luciferase activity is reported on a logarithmic scale. Results are representative of three independent 
experiments. Error bars represent the SD of triplicate tests. (C) (upper panels) Fluorescence and bright field 
microscope images of cells derived from fresh SS samples infected with a lentiviral vector expressing both 
ΔNLEF-1 and RFP, 200X magnification; (lower panels) AXIN2 message assessed by Q-PCR. (D) Graphical 
representation and statistical analysis of PLA using anti-β − catenin (mouse) and anti-LEF-1(goat) antibodies in 
unstimulated or 24 hr recombinant Wnt3a-stimulated C3H10T1/2pLIVc (pLIVc) and C3H10T1/2SS18-SSX1-V5  
(SS-V5) cells. PLA signal quantification was performed as described in materials and methods. Bars represent 
the S.E.M. (E) Luciferase activity after transient transfection with TOP- and FOP-Flash plasmids of resting 
or 24 hr recombinant Wnt3a-stimulated C3H10T1/2pLIVc (pLIVc) and C3H10T1/2SS18-SSX1-V5 (SS-V5) cells. 
Results are reported as the ratio of TOP-Flash:FOP-Flash activity and are representative of three independent 
experiments. Error bars represent the SD of triplicate tests.
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C3H10T1/2SS18-SSX1-V5 cells (Fig. 2A black histograms), meaning that the robust induction of AXIN2 by SS18-SSX 
was not significantly affected. The same held true for other Wnt target genes induced by SS18-SSX, including 
LGR5, EDN1, RHOU, NRP2 and DACT1 (data not shown). To verify that ΔN LEF-1 inhibits LEF-1/β -catenin 
complex activity at the AXIN2 promoter in C3H10T1/2 cells, we compared AXIN2 mRNA in C3H10T1/2pLIVc 
and C3H10T1/2SS18-SSX1-V5 cells expressing or not ΔN LEF-1 stimulated with recombinant mouse Wnt3a (Fig. 2A 
gray histograms). AXIN2 message was induced roughly 700 fold by Wnt3a in C3H10T1/2pLIVc cells and the induc-
tion was strongly blunted by ΔN LEF-1 (Fig. 2A). In C3H10T1/2SS18-SSX1-V5 cells, Wnt3a stimulation increased 
SS18-SSX-induced AXIN2 expression about 3 fold. The observed increase was attenuated by ΔN LEF-1 but 
AXIN2 expression remained elevated, consistent with the lack of a significant inhibitory effect of ΔN LEF-1 on 
SS18-SSX-dependent AXIN2 induction (Fig. 2A). Accordingly, the luciferase reporter system described above 
in C3H10T1/2SS18-SSX1-V5 cells expressing either ΔN LEF-1 or an empty vector showed that the robust luciferase 
activity induced by SS18-SSX1 was unaffected by the presence of ΔN LEF-1 (Fig. 2B). In primary SS11 and SS12 
cells, ΔN LEF-1 not only failed to repress but tended to enhance AXIN2 expression (Fig. 2C).
Interaction between β -catenin and LEF-1 was assessed in vivo in C3H10T1/2SS18-SSX-V5 and C3H10T1/2pLIVc 
cells by proximity ligation assay (PLA), using a polyclonal goat anti-LEF-1 and a mouse anti-β -catenin antibody. 
Cells stimulated with recombinant mouse Wnt3a for 16 hours provided a positive control. In baseline conditions, 
the number of fluorescent foci, that represent interactions, in C3H10T1/2SS18-SSX1-V5 was comparable to that in 
resting C3H10T1/2pLIVc cells (Fig. 2D). The same held true for interactions between β -catenin and TCF3/4 as 
assessed using rabbit anti-β -catenin and mouse anti-TCF3/4 antibodies (data not shown). The number of foci 
increased comparably in the nuclei of Wnt3a stimulated C3H10T1/2 and C3H10T1/2SS18-SSX1-V5 cells (Fig. 2D). 
SS18-SSX expression in C3H10T1/2 cells therefore does not prevent β -catenin – TCF/LEF complex formation in 
response to Wnt ligands.
To verify that TCF/LEF participate in SS18-SSX1-mediated induction of AXIN2 mRNA, we measured tran-
scriptional TCF/LEF activity in C3H10T1/2pLIVc and C3H10T1/2SS18-SSX1-V5 stimulated with 0.1 μM recombinant 
WNT3a or vehicle (PBS), using TOP-FLASH luciferase reporter and corresponding negative control FOP-FLASH 
plasmids (Fig. 2E). TOP luciferase activity was low in resting C3H10T1/2pLIVc cells, consistent with negligible Wnt 
signaling. By contrast, C3H10T1/2SS18-SSX1-V5 cells displayed an increase in the TOP/FOP reporter ratio, compara-
ble to that induced by WNT3a stimulation of parental cells. Combined SS18-SSX expression and WNT3a stim-
ulation had a synergistic effect. Together with luciferase-based assay results that showed no effect of ΔN LEF-1 
on SS18-SSX-dependent AXIN2 expression (Fig. 2B), these observations suggest that LEF-1 may participate 
in SS18-SSX-mediated induction of AXIN2 without binding to β -catenin. We therefore interrogated β -catenin 
implication in SS18-SSX-dependent AXIN2 expression in the absence of exogenous Wnt signals.
Depletion of β -catenin was achieved using either a pool of siRNAs (Fig. 3) or inducible shRNA (not shown) 
and its effect was tested on both SS18-SSX and WNT3a mediated AXIN2 induction in C3H10T1/2 cells. The 
siRNA pool produced robust depletion of the protein as assessed by Western blot analysis (Figure 3 panel A), 
but the depletion was slightly less efficient in cells expressing SS18-SSX. In the presence of SS18-SSX a 75–80% 
decrease in β -catenin mRNA, as assessed by qRT-PCR, resulted in a 50% decrease in AXIN2 message (Figure 3 
panel B). In Wnt3a stimulated cells β -catenin depletion, assessed at 95% by qRT-PCR, resulted in the return of 
AXIN2 expression to baseline levels (Figure 3B right panel). Similar results were obtained using inducible shRNA 
in SS18-SSX expressing cells (not shown).
Together these observations suggest that whereas SS18-SSX does not prevent β -catenin-TCF/LEF asso-
ciation in response to Wnt ligand stimulation, in the absence of Wnt ligands it induces TCF-LEF-dependent 
AXIN2 expression without involving β -catenin-TCF/LEF complexes. Nevertheless, β -catenin may contribute to 
SS18-SSX-induced AXIN2 expression, possibly by promoter de-repression.
AXIN2 repressor complexes in C3H10T1/2 cells. Although the four TCF family members (TCF1, TCF3, 
TCF4 and LEF-1) share the same protein interaction domains, mounting evidence suggests that each member has 
individual properties that may be responsible for unique functions in defined contextual settings28,36. Thus, the 
same TCF/LEF family members may behave as transcriptional repressors or activators in different cell types and 
may transition from transcriptional repressors to transcriptional activators in response to Wnt ligands. In addi-
tion, inactivation alone of their repressor activity has been reported to suffice to drive target gene expression36. 
We therefore addressed the implication of each TCF family member in transcriptional repression and activation 
of AXIN2 in resting, Wnt3a-stimulated and SS18-SSX-expressing C3H10T1/2 cells and then assessed the impli-
cation of HDAC in AXIN2 repression.
TCF/LEF family members. The implication of TCF/LEF family members in AXIN2 expression in C3H10T1/2 
cells was addressed by their individual depletion or overexpression (Fig. 4). TCF1 was neither expressed nor 
induced by SS18-SSX in C3H10T1/2 cells (not shown) and was not considered further. Depletion of TCF3 and 
TCF4/LEF-1was achieved using a pool of 4 and pools of 3 siRNAs, respectively. HA-tagged LEF-1 and TCF4 
were over-expressed using lentiviral infection and lipid-mediated transfection, respectively. Depletion and 
over-expression were assessed by qRT-PCR and Western blot analysis (TCF4 and LEF-HA, Fig. 4C,E) and by 
immunofluorescence (endogenous LEF-1, Fig. 4D).
In the absence of exogenous stimuli, changes in LEF-1 expression levels did not affect AXIN2 expression sig-
nificantly (Fig. 4A top panel). Over-expression of TCF4 also had no effect but its depletion consistently induced 
AXIN2 (Fig. 4A top panel). By contrast, TCF3 depletion caused mild AXIN2 repression, below statistical signif-
icance. These observations suggest that in resting C3H10T1/2 cells complexes containing TCF4 participate in 
AXIN2 promoter silencing whereas TCF3 and LEF-1 do not appear to be implicated in any significant manner.
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Upon Wnt3a stimulation of C3H10T1/2 cells TCF4 continued to exert repression as reflected by moderate 
AXIN2 up- and downregulation following its depletion and overexpression, respectively (Fig. 4A middle panel). 
LEF-1 and TCF3 by contrast participated in activation as depletion of TCF3 decreased AXIN2 expression and 
LEF1 over-expression enhanced it (Fig. 4A middle panel).
In the presence of SS18-SSX, TCF4 displayed similar activity: its depletion increased whereas its 
over-expression mildly repressed AXIN2 expression (Fig. 4A lower panel). In contrast to WNT3a stimulation, 
LEF-1 was associated with a repressor function in the presence of SS18-SSX, as LEF-1 depletion increased whereas 
LEF1-HA over-expression decreased AXIN2 expression (Fig. 4A lower panel). TCF3 did not play a relevant role.
Histone deacetylase. HDAC involvement in AXIN2 promoter silencing in C3H10T1/2 cells was verified by anal-
ysis of Histone H3 lysine9 acetylation (H3K9Ac) and by assessing the effect of the HDAC inhibitor trichostatin A 
(TSA) on AXIN2 transcripts (Fig. S2). Treatment for 6 (or 16) hrs with 250 nM TSA induced a 6 fold increase in 
AXIN2 mRNA in C3H10T1/2 cells, whereas in resting STO cells, which display a 12 fold higher AXIN2 expres-
sion (Fig. S2B), the same treatment produced only a 2 fold increase (Fig. S2A). Comparison of H3K9Ac at the 
AXIN2 promoter in these two cell types revealed a higher content in STO cells (Fig. S2C). Thus, HDAC partici-
pates in regulating AXIN2 promoter repression in resting C3H10T1/2 cells.
In vivo validation of interactions implicated in the formation of complexes that regulate AXIN2 
promoter activity. In vivo interactions between HDAC and LEF-1, HDAC and TLE and TLE and LEF-1 
were analyzed by PLA using rabbit anti-HDAC, goat anti-LEF-1 and mouse or rabbit anti-TLE antibody (Fig. 5A 
upper panel and Fig. S3). Assessment of the distribution of TLE, LEF-1, TCF3/4 and HDAC by immunofluores-
cence confirmed nuclear localization of TLE, prevalent nuclear localization of LEF-1and TCF3/4 and nuclear 
and cytoplasmic localization of HDAC (Figs S4 and 4D). Anti-LEF-1 and anti-HDAC and anti-TCF3/4 and 
anti-HDAC antibodies revealed a high number of foci in 100% of cells, as did anti-TLE and anti-HDAC antibod-
ies (Fig. 5A upper panel), whereas the number of foci associated with anti-TLE and anti-LEF-1 antibodies was 
barely above the background (Fig. S3). Repression of the AXIN2 promoter in C3H10T1/2 cells thus appears to 
be maintained primarily by HDAC/LEF-1, HDAC/TCF3/4 and HDAC/TLE-containing complexes. We therefore 
explored SS18-SSX association with the different repressor and activator complex components in vivo.
Figure 3. β−catenin participates in SS18-SSX1-induced AXIN2 promoter activity. C3H10T1/2pLIVc (pLIVc) 
and C3H10T1/2SS18-SSX1-V5 (SS-V5) cells were depleted of β − catenin using a pool of siRNAs or control siRNA 
(AllStars). Depletion was verified by Western blot and densitometric analysis using imageJ (Fig. 3A) or by qPCR 
(Fig. 3B). The effect on AXIN2 transcript levels was measured by Q-PCR (Fig. 3B).
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SS18-SSX interacts with TLE, LEF-1, TCF3/4 and HDAC but not with β−catenin. In vivo asso-
ciation of SS18-SSX with complex components implicated in AXIN2 promoter silencing was assessed by PLA 
(Fig. 5A lower panel, Figs S3 and S4). Anti-TLE1, 2, 3, 4 and anti-V5 antibodies produced nuclear foci signif-
icantly above the background but only in about 30% of cells, far below the fraction of SS18-SSX-V5 positive 
cells. Anti-V5 and anti-HDAC1 antibodies generated a high number of nuclear foci in all of the cells expressing 
SS18-SSX-V5, consistent with robust association between the fusion protein and HDAC. Interactions between 
SS18-SSX and LEF-1 were detected in C3H10T1/2SS18-SSX1-V5 cells stably expressing C-terminal HA-tagged LEF-
1(Fig. 4E and data not shown) and association between SS18-SSX and endogenous LEF-1 was confirmed by 
comparison of PLAs in C3H10T1/2pLIVc and C3H10T1/2SS18-SSX1-V5 cells using mouse anti-V5 and goat-anti LEF-1 
antibody (Fig. 5A lower panel and S3). Rabbit anti-V5 and mouse anti TCF3/4 antibody revealed interactions 
between SS18-SSX and endogenous TCFs as well (Fig. 5A lower panel and S3). However, anti-β -catenin and 
anti-V5 antibody did not show increased numbers of foci compared to the background, suggesting absence 
of SS18-SSX-β -catenin interaction in C3H10T1/2 cells (Fig. S3). Importantly, all of the interactions observed 
in C3H10T1/2 cells were context-independent and were detected in the synovial sarcoma cell lines FUJI and 
HS-SYII expressing a V5-tagged SS18-SSX1 protein (Fig. S5) as well as in STO fibroblasts (data not shown).
Figure 4. Implication of TCF/LEF family members in regulating AXIN2 expression. (A) Q-PCR analysis of 
AXIN2 in unstimulated or Wnt3a-stimulated (0.1 μM, 24 hrs) C3H10T1/2pLIVc (pLIVc) and C3H10T1/2SS18-SSX1-V5 
(SS-V5) cells depleted of or over-expressing individual TCF members as indicated. Depletion was achieved 
using a pool of specific or control siRNA (AllStars). (B) (first 3 columns): Depletion of each TCF/LEF (as 
indicated) was verified in each cell population by Q-PCR. B (right columns): Over-expression of TCF4 was 
measured by Q –PCR. (C) TCF4 depletion was verified by Western blot analysis using an anti-TCF4 antibody 
and anti-β actin as loading control; (D) LEF1 depletion was verified by immunofluorescence microscopy using 
an anti-LEF1 antibody. (E) Over-expression of HA-tagged LEF1 was assessed by Western blot analysis using an 
anti-HA antibody and anti-tubulin antibody as loading control.
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Figure 5. Interactions among SS18-SSX, HDAC1, TCFs, TLE and LEF-1. (A) Graphical representation 
and statistical analysis of PLAs using antibodies against the indicated proteins in C3H10T1/2pLIVc (pLIVc) and 
C3H10T1/2SS18-SSX1-V5 (SS-V5) cells. PLA signal quantification was performed as described in materials and methods. 
Corresponding representative fluorescence microscopy images are shown in Fig. S3. (B) Immunoprecipitation (IP) 
was done on C3H10T1/2pLIVc (pLIVc) and C3H10T1/2SS18-SSX1-V5 (SS-V5) cell lysates using anti-V5 monoclonal 
antibody (a and b), normal goat serum (NGS) or a goat polyclonal α -LEF-1 antibody (c). Immunoprecipitates 
were subjected to 10% SDS-PAGE together with total lysates and revealed using anti- TCF4 (a), anti-HDAC1 (b) or 
monoclonal α -V5 antibody (c).TCF4, HDAC1, SS18-SSX-V5, LEF1, immunoglobulins and protein size markers are 
indicated. (C) Native gel electrophoresis of C3H10T1/2pLIVc (pLIVc) and C3H10T1/2SS18-SSX1-V5 (SS-V5) cell lysates. 
Equal amounts of each sample were loaded onto four wells on the same 5% gel, subjected to electrophoresis and 
transferred onto nitrocellulose membranes. After blotting the nitrocellulose membrane was cut and incubated with 
the indicated antibodies. The arrow indicates the co-migration position of HDAC1, TCF4 and SS18-SSX-V5.
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All of the observed interactions were then tested in vitro. Co-immunoprecipitation from C3H10T1/2pLIVc 
and C3H10T1/2SS18-SSX1-V5 cell lysates was performed using either an anti-V5 (Fig. 5B,a,b) or an anti-LEF-1 anti-
body (Fig. 5B,c). Western blot analysis revealed HDAC1and TCF4 in anti-V5 antibody immunoprecipitates and 
SS18-SSX1 in anti-LEF-1 antibody immunoprecipitates.
The relationship between β -catenin and SS18-SSX-containing complexes was further assessed using native 
gel electrophoresis of C3H10T1/2pLIVc and C3H10T1/2SS18-SSX and probing the resulting blots with anti-TCF4, 
anti-HDAC, anti-V5 and anti-β -catenin antibodies (Fig. 5C). In resting C3H10T1/2pLIVc cells β -catenin, TCF4 
and HDAC1 co-migrated in the gel consistent with their participation in the same complex. The same approach 
in C3H10T1/2SS18-SSX cells revealed that SS18-SSX co-migrates with TCF4 and HDAC but not with β -catenin, 
which migrates to a distinct location in the gel. These observations support the existence of SS18-SSX-associated 
complexes that contain both HDAC and TCF from which β -catenin is excluded.
SS18-SSX, TCF4 and HDAC are enriched at the AXIN2 promoter. We next asked whether the 
observed associations are DNA-dependent. PLAs using paired antibodies for the identified interactors were 
conducted in C3H10T1/2pLIVc and C3H10T1/2SS18-SSX1-V5 cells followed by DAPI counterstaining or in cells 
pre-stained with 5 μM DAPI to disrupt DNA prior to fixation. DAPI penetration of living cells was verified by 
fluorescence microscopy and DNA-independent interactions between actin and tubulin were assessed to exclude 
possible effects of DAPI pre-staining on PLA itself (Fig. 6A). Immunofluorescence staining of SS18-SSX, HDAC, 
LEF-1 and TCF3/4 using the same antibodies was done in parallel in both conditions to ascertain that DAPI 
pre-staining did not affect antibody reactivity (Fig. S6). PLA revealed that SS18-SSX association with HDAC, 
LEF-1 and TCF3/4 was strongly reduced in cells pre-treated with DAPI consistent with DNA-dependence of all 
of the observed interactions (Fig. 6A).
SS18-SSX, TCF3/4 and HDAC presence at the AXIN2 promoter was verified by chromatin immunoprecip-
itation (ChIP) using rabbit anti-V5, anti-HDAC and anti-TCF3/4 antibodies (Fig. 6B). Capture of the entire 
complex was optimized using a dual crosslinking protocol for HDAC ChIP with 1% PFA and ethylene glycol-bis 
(EGS)37 or an SDS-free lysis buffer. Enrichment of SS18-SSX was observed in all regions analyzed. In the pres-
ence of SS18-SSX, TCF3/4 enrichment occurred primarily at the region upstream of the first ATG close to the 
T2 TCF/LEF binding site (− 274 to − 182), whereas HDAC enrichment was also observed downstream, within 
the region containing the T6 TCF/LEF binding site (+ 1554 + 1936)29. Together, these observations indicate 
DNA-dependence of SS18-SSX interaction with HDAC and TCF/LEF and association of the resulting complexes 
with the AXIN2 promoter.
SS18-SSX does not dissociate repressor complexes. Assessment of possible SS18-SSX-mediated dis-
ruption of repressor complexes was conducted using PLA to compare interactions between LEF-1 and HDAC, 
TCF3/4 and HDAC, TLE and HDAC and TLE and LEF-1 in C3H10T1/2pLIVc and C3H10T1/2SS18-SSX1-V5 cells 
(Fig. 5A upper panel). SS18-SSX expression did not significantly alter interactions between HDAC and LEF-1, 
TCF3/4 or TLE. Wnt3a stimulation of C3H10T1/2pLIVc (0.1 μM for 16 h) did not result in significant dissociation 
of HDAC from LEF-1(not shown) whereas it increased association between LEF-1 and β -catenin, as discussed 
earlier (Fig. 2D). In vivo observations using PLA therefore suggest ternary HDAC, LEF-1 and β -catenin complex 
formation upon Wnt3a stimulation and HDAC, LEF-1 and SS18-SSX complex formation in C3H10T1/2SS18-SSX1-V5 
cells in the absence of Wnt ligands.
SS18-SSX enhances nuclear β-catenin translocation and degradation. Because β -catenin does 
not interact with SS18-SSX in vivo yet affects SS18-SSX-dependent induction of AXIN2 even in the absence of 
Wnt ligands, albeit not as part of a complex with TCF/LEF1, we addressed its fate in SS18-SSX expressing cells. 
Localization of β -catenin was primarily cytoplasmic in resting C3H10T1/2pLIVc cells (Fig. S7A) but mostly peri-
nuclear and less markedly nuclear in C3H10T1/2SS18-SSX1-V5 cells. Nuclear β -catenin localization was comparable 
in C3H10T1/2SS18-SSX1-V5 cells, parental C3H10T1/2 cells stimulated for 24 hrs with recombinant murine Wnt3a, 
unstimulated SS11 cells and SS18-SSX-expressing STO fibroblasts (Fig. S7A). As enhancement of β -catenin trans-
location to the nucleus occurs in NIH3T37 and STO cells (Fig. S7A) where SS18-SSX does not induce AXIN2 
message, nuclear anti-β -catenin antibody staining alone does not predict transcriptional effects.
The moderate nuclear β -catenin accumulation in C3H10T1/2SS18-SSX1-V5, Wnt3a stimulated C3H10T1/2 
and SS11 cells despite enhanced translocation, may reflect increased nuclear degradation. Accordingly, 
GSK3β -dependent phosphorylation of β -catenin on Thr41, Ser33 and Ser37, which precedes proteosomal deg-
radation38, was increased in the presence of SS18-SSX1 (Fig. S7B,b). Treatment with the proteasome inhibitor 
MG132 restored β -catenin protein levels in C3H10T1/2SS18-SSX1-V5 to those observed in wt and C3H10T1/2pLIVc 
cells consistent with enhanced proteosomal degradation in C3H10T1/2SS18-SSX1-V5 cells (Fig. S7B, MG132). The 
increase in nuclear β -catenin resulting from SS18-SSX-stimulated translocation may therefore be restricted by 
correspondingly increased degradation, which may provide a mechanism for limiting nuclear β -catenin levels. 
Consistent with this notion and with recent observations by others39 we observed that β -catenin degradation in 
SS18-SSX-expressing cells was primarily nuclear (data not shown).
SS18-SSX promotes nuclear β-catenin-HDAC interactions and affects HDAC activity at the 
AXIN2 promoter. Based on the observation that β -catenin participates in SS18-SSX-dependent AXIN2 
induction, we interrogated the putative mechanism by which it does so. Nuclear β -catenin is suggested to pro-
mote transcriptional de-repression by removing HDAC from LEF-1 or by first disrupting TLE-LEF-1 inter-
action and then binding and inactivating HDAC27. PLA assessment of β -catenin interaction with HDAC in 
C3H10T1/2 cells in the presence and absence of SS18-SSX (Figs 7A and S8) using mouse anti-β -catenin and 
rabbit anti-HDAC1 antibody revealed both nuclear and cytoplasmic foci suggesting interaction in both 
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compartments. However, C3H10T1/2SS18-SSX1-V5 cells displayed fewer cytoplasmic but significantly more nuclear 
foci than C3H10T1/2pLIVc cells (Fig. S8A). Because HDAC localization, as assessed by immunofluorescence using 
anti-HDAC antibody, was comparable and predominantly nuclear in C3H10T1/2pLIVc and C3H10T1/2SS18-SSX1-V5 
cells (not shown), enhancement of nuclear β -catenin-HDAC1 interactions may be explained at least in part by 
the moderate SS18-SSX-dependent increase in nuclear β -catenin. As absence of β -catenin-SS18-SSX association 
suggests that the fusion protein is not part of a complex containing both HDAC and β -catenin, even moderately 
augmented nuclear β -catenin may help sequester HDAC from LEF-1 and thereby contribute to AXIN2 promoter 
de-repression. β -catenin-dependent dissociation of the complex may facilitate subsequent SS18-SSX binding to 
HDAC and TCF/LEF-1. Consistent with this notion, LEF-1-depleted C3H10T1/2SS18-SSX1-V5 cells (Fig. 4D) sub-
jected to PLA using anti-HDAC and anti-V5 antibodies revealed increased numbers of foci suggesting increased 
HDAC-SS18-SSX association upon LEF-1 depletion (Fig. 7B and S8).
Because HDAC plays a central role in TCF/LEF repression, we explored the structural basis of 
SS18-SSX-HDAC interaction and its functional consequences by comparing the effect of the class I and II HDAC 
Figure 6. DNA dependence of SS18-SSX interactions. (A) Graphical representation and statistical analysis 
of PLAs using antibodies against the indicated proteins. C3H10T1/2SS18-SSX1-V5 cells were pre-stained with 5 μM 
DAPI for 30 min and subjected to PLA or subjected to PLA and then counterstained with DAPI. PLA signal 
quantification was performed as described in materials and methods. (B) ChIP using anti-TCF3/4, anti-V5 
and anti-HDAC1 antibodies in C3H10T1/2pLIVc and C3H10T1/2SS18-SSX1-V5 cells. Results are expressed as fold 
enrichment of values obtained with rabbit or mouse IgG immunoprecipitates, after normalization for the total 
amount of input chromatin. Results are representative of three independent experiments. Error bars represent 
the SD of triplicate PCR tests.
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inhibitor trichostatin A (TSA) on AXIN2 transcripts in C3H10T1/2pLIVc and C3H10T1/2SS18-SSX1-V5 cells (Fig. S2A). 
TSA blocks HDAC by binding to its catalytic site40. In the presence of SS18-SSX, HDAC inhibition by TSA was 
partially impaired as only a 3 fold increase in AXIN2 message occurred in C3H10T1/2SS18-SSX1-V5 cells compared 
to a 6 fold increase in C3H10T1/2pLIVc (Fig. S2A). The reduced efficacy of TSA in C3H10T1/2SS18-SSX1-V5 cells sup-
ports a model in which SS18-SSX binds to or modifies the catalytic site of HDAC recognized by TSA and impedes 
TSA binding. Consistent with this notion, 250 nM TSA markedly reduced the number of HDAC-SS18-SSX foci 
in C3H10T1/2SS18-SSX1-V5 cells suggesting that either SS18-SSX binds HDAC in the vicinity of its catalytic site and 
is displaced by TSA or that TSA binding alters HDAC conformation in a way that decreases SS18-SSX binding 
(Fig. 7C). TSA treatment also strongly inhibited HDAC-LEF-1 interaction in baseline conditions but failed to 
do so in the presence of SS18-SSX (Figs 7D and S8). PLAs using anti-V5 and anti-LEF-1 antibodies showed 30% 
reduction in the number of SS18-SSX/LEF-1 interactions, upon TSA treatment (Figs 7E and S8), suggesting their 
dependence on intact HDAC availability and supporting ternary complex formation.
SS18-SSX expression in C3H10T1/2 cells increases Histone H3 acetylation at the AXIN2 pro-
moter and induces changes in chromatin accessibility. By modulating HDAC activity, SS18-SSX 
may alter histone H3 acetylation and thereby participate in establishing a permissive chromatin structure for 
TCF-LEF-driven transcription. To address the effect of SS18-SSX on HDAC activity at the AXIN2 promoter, 
chromatin immunoprecipitation (ChIP) was performed using anti-histone H3K9Ac antibody and purified pre-
cipitated DNA was analyzed by qPCR using several primer pairs that anneal to different promoter regions (Table 
S7). Histone H3K9 acetylation underwent significant changes in response to SS18-SSX expression in C3H10T1/2 
cells (Fig. 8A). Acetylation was increased at all the regions analyzed, particularly at those close to the TSS (exon 
2) that contain the T4-T8 TCF/LEF binding sites (Fig. 8A, 1554–3268). By contrast, SS18-SSX expression in 
STO cells (Fig. 8A) resulted in a slight decrease in histone H3K9Ac. Thus, AXIN2 promoter inducibility by 
SS18-SSX must depend, at least in part, on conditions that allow the fusion protein to affect acetylating and/
or de-acetylating enzyme activity. Although these findings do not exclude the possible contribution of histone 
acetylases (HATs), they support the notion that HDAC activity at the AXIN2 promoter is reduced upon SS18-SSX 
Figure 7. (A) SS18-SSX expression promotes interaction between β − catenin and HDAC1 in nuclei. 
Graphical representation with statistical analysis of PLAs using antibodies against the indicated proteins in 
C3H10T1/2pLIVc (pLIVc) and C3H10T1/2SS18-SSX1-V5 (SS-V5) cells. Correspondent representative fluorescence 
microscopy images are reported in Fig. S7. (B) LEF-1 depletion promotes SS18-SSX-HDAC1 association. 
Graphical representation of PLA as in (A). (C) TSA treatment inhibits SS18-SSX association with HDAC1. 
Representative fluorescence microscopy images of PLA using anti-V5 and anti-HDAC1 antibodies in 
C3H10T1/2SS18-SSX1-V5 cells stimulated with 250 nM TSA or DMSO for 16hrs. Scale bar: 5 μm. (D,E) Effect of 
TSA treatment on LEF-1 interactions with HDAC (D) and SS18-SSX (E); graphical representation of PLA as in 
(A).
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expression. Consistent with this notion treatment of C3H10T1/2pLIVc and C3H10T1/2SS18-SSX1-V5 cells with 50 μM 
anacardic acid or 20 μM curcumin did not alter AXIN2 expression excluding a major role for HATs (not shown). 
Histone acetylation leads to partial de-condensation of chromosomal domains that augments DNA accessi-
bility and facilitates the action of the transcriptional machinery. To determine whether SS18-SSX1 may affect 
AXIN2 transcription by altering chromatin conformation, chromatin accessibility assays were performed using 
methylation-independent restriction enzyme hydrolysis and real-time PCR (Fig. 8B). Primer pairs spanning 
sequences containing MspI sites were chosen within several regions of the AXIN2 promoter and primer pairs 
spanning sequences of the AXIN2 promoter that lack MspI sites were used as negative controls. GAPDH-specific 
primer pairs were used for normalization (Table S7). Compared to C3H10T1/2pLIVc, C3H10T1/2SS18-SSX1-V5/HA 
cell-derived DNA displayed increased cleavage by MspI when primers spanning the regions –330 − 246 and 
–147 − 51 were used. These observations suggest that SS18-SSX induces histone acetylation with corresponding 
chromatin conformation changes at the AXIN2 promoter.
Discussion
We have shown cell context-independent SS18-SSX association with key transcriptional regulators of the Wnt 
pathway, including the transcription factors LEF-1 and TCF4 and the transcriptional repressors TLE and HDAC. 
In a permissive context, provided here by pluripotent mesenchymal C3H10T1/2 cells that may resemble candidate 
cells of origin of SS41–44,2,45, SS18-SSX induced a partial Wnt gene expression signature. Particularly striking was 
the robust induction of AXIN2, one of the least context-dependent Wnt target genes, reaching levels comparable 
Figure 8. SS18-SSX promotes Histone H3K9 acetylation and chromatin accessibility at the AXIN2 
promoter. (A) Histone H3K9Ac ChIP in C3H10T1/2pLIVc (pLIVc), C3H10T1/2SS18-SSX1-V5 (SS-V5) and STO cells 
infected with SS18-SSX-V5 or empty pLIVc. Cross-linked chromatin was sonicated and immunoprecipitated 
with an anti Histone H3K9Ac antibody or rabbit IgG. Co-immunoprecipitated DNA was quantified by real-time 
PCR using primer pairs annealing to the mouse AXIN2 promoter region at the indicated positions. Results are 
expressed as fold enrichment of values obtained with rabbit IgG precipitates after normalization for the total 
amount of input chromatin. Results are representative of three independent experiments. Error bars represent 
the SD of triplicate PCR tests. (B) Chromatin accessibility tests in C3H10T1/2pLIVc (pLIVc), C3H10T1/2SS18-SSX1-V5 
(SS-V5) and C3H10T1/2SS18-SS1-HA (SS-HA) cells. Positions of primers used for amplification of MspI CHART 
products by qRT-PCR are reported with approximate location of ATGs and transcription factor binding sites. 
Results are representative of three independent experiments. Error bars represent the SD of triplicate PCR tests.
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to those observed in primary SS cells. Interrogation of the mechanistic basis for these observations revealed that 
SS18-SSX, TCF/LEF and HDAC are enriched at the same segment of the AXIN promoter, as demonstrated by 
ChIP analysis, and that SS18-SSX can induce the TOP-Flash reporter in the absence of Wnt ligand stimulation, 
supporting TCF/LEF-1 implication in SS18-SSX-associated transcriptional activation. However, SS18-SSX did 
not interact with β -catenin, despite enhancing its recruitment to the nucleus, and formed complexes with TCF/
LEF, HDAC and TLE devoid of β -catenin. Expression of ΔN-LEF, which binds DNA but not β -catenin, failed to 
affect SS18-SSX-mediated induction of AXIN2 as well as of LGR5, EDN1, RHOU, NRP2 and DACT1 Wnt target 
gene expression, arguing against β -catenin-TCF/LEF complex involvement and suggesting that SS18-SSX may 
substitute for at least some β -catenin functions toward induction of TCF/LEF target genes.
In response to Wnt ligands, β -catenin translocates to the nucleus where it displaces or helps release TCF/
LEF-associated HDAC and TLE/Groucho. It then binds TCF/LEF and promotes target gene induction by recruit-
ing transcriptional activators46, as well as chromatin remodeling complexes including at the very least Brg1/SWI/
SNF and p300CBP47. Similar to β -catenin, SS18-SSX not only binds TCF/LEF and HDAC but constitutes a part 
of the Brg1/SWI/SNF complex whose physiological activity is to create nucleosome-depleted regions at core pro-
moters and regulatory sequences, facilitating transcription factor access to DNA. Thus, SS18-SSX and β -catenin 
may use analogous strategies to induce Wnt target genes, but elaborate distinct molecular complexes resulting 
in non-identical effects as illustrated by the partial Wnt signature induced by SS18-SSX. Although SS18-SSX 
and β -catenin do not associate physically, they appear to have a relevant functional relationship. Depletion of 
β -catenin in SS18-SSX expressing cells resulted in a 50% decrease in SS18-SSX-mediated upregulation of AXIN2 
expression suggesting retention of its role in de-repression of Wnt target gene promoters. By facilitating nuclear 
translocation of β -catenin, while excluding it from complexes that it forms with TCF/LEF, SS18-SSX may aug-
ment β -catenin availability for HDAC sequestration/inactivation, which is supported by increased nuclear 
HDAC-β -catenin interactions in SS18-SSX expressing cells, as shown by PLA.
Although SS18-SSX may utilize β -catenin to relieve promoter repression, our observations suggest that 
SS18-SSX itself participates in AXIN2 promoter de-repression by inhibiting HDAC in ternary DNA-bound 
complexes. Formation of ternary complexes composed of SS18-SSX, HDAC and TCF/LEF is supported by 
co-migration of the three proteins in native gels, their presence in the same fractions of glycerol gradients (not 
shown) and the observation that HDAC-LEF1 interactions are unaltered by SS18-SSX expression. Moreover, the 
30% reduction in the number of SS18-SSX-LEF-1 PLA foci following TSA treatment suggests partial dependence 
of the interaction on intact HDAC availability. The function of LEF-1 as transcriptional repressor in the pres-
ence of SS18-SSX also supports ternary complex formation. Nevertheless, SS18-SSX may also engage in binary 
complexes with LEF-1 and HDAC, as the increase in the number of HDAC-SS18-SSX interactions upon LEF-1 
depletion suggests a dynamic equilibrium between complexes containing all three proteins and only SS18-SSX/
HDAC or LEF-1/HDAC. Comparison of SS18-SSX/HDAC and LEF-1/HDAC with SS18-SSX/LEF-1 interactions 
suggests that this is indeed the case as the first two generate a much higher number of PLA foci than the last. The 
effect of β -catenin depletion on AXIN2 expression raises the possibility that SS18-SSX may fulfill its function sub-
sequent to β -catenin-mediated dissociation of HDAC from TCF/LEF-1. The increased SS18-SSX-HDAC interac-
tion upon LEF-1 depletion suggests that SS18-SSX-HDAC association may precede ternary complex formation.
Despite binding Wnt transcription factors, SS18-SSX does not prevent Wnt ligand-induced target gene expres-
sion but rather appears to have a synergistic effect with canonical Wnt signaling. These observations are consistent 
with the possibility that SS18/SSX interacts with TCF/LEF at a fraction of their DNA binding sites on the AXIN2 
promoter which it de-represses by blocking HDAC activity, inducing local chromatin changes and promoting 
nuclear translocation of available β -catenin to enhance HDAC inactivation/sequestration. If only a fraction of 
DNA-bound TCF/LEF-1 is occupied by SS18-SSX, stimulation by Wnt ligands can be expected to further aug-
ment AXIN2 expression by activating canonical β -catenin-Wnt signaling. However, SS18-SSX interactions with 
TCF/LEF and TOP flash data that support TCF/LEF implication in SS18-SSX-dependent induction of AXIN2 
expression do not exclude the participation of a distinct SS18-SSX-associated transcription factor.
Taken together, our observations suggest that by interacting with TCF/LEF and utilizing β -catenin as a tran-
scriptional de-repressor, SS18-SSX can induce a partial Wnt expression signature in the absence of Wnt ligands 
without excluding an additive effect of Wnt ligand-dependent stimulation. Synovial sarcoma cells may thus pos-
sess a dual mechanism of ensuring Wnt pathway activity that may be essential for defined stages of their devel-
opment possibly including stemness maintenance and limiting differentiation. The ability of SS18-SSX to engage 
Wnt signaling without resorting to Wnt ligands may have important therapeutic implications at it suggests that 
mere impairment of canonical Wnt signaling may not suffice to abrogate SS development.
Materials and Methods
Antibodies and reagents. Antibodies used for western blot, immunoprecipitation, immunofluorescence or 
proximity ligation assay (PLA) were: mouse anti-V5epitope (Invitrogen Carlsbad, CA), rabbit polyclonal anti-V5 
tag (Abcam, Cambridge UK), monoclonal anti-HA (Covance Research Product Inc Geneva Switzerland), mouse 
anti-Xpress (Invitrogen), mouse anti-tubulin (Calbiochem), rabbit anti-α /β tubulin (Cell Signaling), mouse 
anti-actin clone AC-40 (SIGMA), anti-TCF4 and anti-LEF-1 (Santa Cruz Biotechnology inc. Germany), rabbit 
anti-TCF4 (C48H11, Cell Signaling), anti-TCF3 + 4 [6F12-3], anti-Histone H3AcK9, anti-HDAC1 Ab7028, anti-
HDAC1 Ab46985 and anti-TLE-1 (Abcam, Cambridge UK), anti-TLE1,2,3,4 (Cell Signaling), mouse anti-β -cat-
enin (BD), β -catenin antibody sampler kit (Cell Signaling, Beverly MA). HRP-conjugated secondary antibodies 
were from Amersham (Goat anti-mouse-HRP) or from Dako, Denmark (goat anti-rabbit and rabbit anti-goat 
HRP). Fluorocrome-conjugated secondary antibodies were from molecular probes. TSA was from SIGMA, 
murine recombinant WNT3a from PreproTech, London UK.
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Ethical issues, cell lines, primary cells and SS samples. All experimental protocols were approved by 
the Ethics Committee of the University of Geneva (protocol 01-172) and of the Canton de Vaud (protocol 131/12) 
and were carried out in accordance with the approved guidelines. Written informed consent was obtained from 
all patients from whom tissues were obtained. C3H10T1/2 and STO cells were from ATCC and were cultured in 
DMEM, 10% FBS; HS-SYII synovial sarcoma cell line were obtained from Riken BioResource Center, Japan, FUJI 
synovial sarcoma cell line was a gift from Dr Francis Hornicek (Massachusetts General Hospital, Boston MA). 
Human mesenchymal stem cells were obtained as described48 and were cultured at low confluence in IMDM, 10% 
FCS, 10 ng/ml PDGF-BB (PeProTech, London, UK). Human satellite cells and human myoblasts were a gift of Dr 
Laumonier (University of Geneva, Switzerland) Human muscle samples, cell dissociation, and clonal culture from 
satellite cells were prepared as described49. Tumor specimens and normal tissues adjacent to cancerous lesions 
obtained after surgical resection, frozen and stored at − 80 °C until use. SS11 and SS12 samples were mechanically 
dissociated and subjected to enzymatic digestion for 40 minutes at 37 °C in IMDM. Details of culture of these cells 
can be found in supplemental methods.
Constructs and cDNA Cloning. cDNA clones, encoding human SS18-SSX1 in frame with a V5 or HA tags 
were obtained using previously described constructs50 as templates for PCR amplification. The mouse Axin-2 
promoter sequence cloned into the pGL3 basic vector, p043 mTcf-4 B and pcDNA3.1/nV5-beta catenin were 
obtained from Adgene, SS18 and SS18-SSX mutants and HA-tagged mouse LEF-1 were constructed as described 
in supplemental methods. The LV-CRE-PLKO.1 and the PLKO.1 vector were from Addgene.
Q-PCR. Q-PCR analysis was done using a HT-7900 instrument (life technology). Endogenous controls for 
normalization were mouse GAPDH, mouse and human cyclophilin and 18S. A ΔCT method and protocols for 
absolute or relative quantification (Applied Biosystems) were used.
Lentivral infection, protein expression and knockdown. Expression of SS18-SSX1-V5, 
SS18-SSX1-HA, SS18-V5, SS18-1-412-V5, XP-SS18-SSX-161-491, LEF-1-HA was achieved using the self inacti-
vating lentiviral Gene Transfer and Expression system pLIVc which produces a floxed proviral genome (Detailed 
information on pLIVc is available on demand). SSXfrag.-V5, mouse TCF4 and V5 tagged β -catenin expression 
were achieved by transfection using Xtreme gene 9 reagent (Roche) using standard transfection protocols. SiRNAs 
were transfected using Interferin siRNA transfection reagent (Polyplus). siRNAs used were s13510 and s13512 for 
SS18 (life technology), sc-35805 for mouse LEF1, sc-43526 for mouse TCF4 (Santa Cruz biotechnology), a pool of 
Mm-Tcf2a, 1,2,3,4 (QUIAGEN) for TCF3 and esiRNA MU-04762-1 (SIGMA)for β -catenin. The shRNA construct 
for β -catenin knockdown was as described51. ShRNA constructs for SS18-SSX were obtained either by cloning the 
sequences targeting the breakpoint (ATATGACCAGATCATGCCCAAG; TGGATATGACCAGATCATGCCC) 
in the lentiviral pLVShRNAmir plasmid or by cloning the sequence reported by Kadoch and Crabtree31 in the 
pLKO.1 lentiviral vector. Depletion was verified by qRT-PCR, Western blot or immunofluorescence.
Affymetrix microarray and bioinformatic analysis. RNA extraction and quality assessment were per-
formed as described50; quality-tested total RNA was used by the Lausanne Genomics Technology Facility (GTF) 
for gene expression profile analysis on Affymetrix Mouse Gene 1.0 ST Arrays (http://www.unil.ch/dafl/). Gene 
expression levels were obtained with RMA52 and differential expression was assessed using a >2 fold change cut 
off for SS18-SSX expression in C3H10T1/2 cells and limma for SS18-SSX expression in STO cells and WNT3a 
stimulation. Enrichment of various functional categories was determined with exact Fisher tests. The source of 
data for the enrichment analysis is reported in the supplemental methods.
Transient transfection and luciferase assays. Cells were transfected with 2 μg of pGL3 vector or the 
pGL3-Axin-2 promoter constructs along with a pGL4 renilla luciferase construct using X-tremeGENE 9 DNA 
transfection reagent (Roche) according to manufacturer’s recommendations. Transfection efficiency was ~60% as 
assessed using a pMAX-GFP control vector (AMAXA). Reporter firefly and renilla luciferase activity were meas-
ured in triplicate 48 hours later on cleared cell lysates using the dual luciferase assay system (Promega, Madison, 
WI, USA), according to manufacturer recommendations.
TOP/FOP-flash assay. TOP/FOP-flash luciferase constructs were a gift from Dr Huelsken (EPFL Lausanne, 
Switzerland). 70% confluent cells in 6 well plates were transfected with TOP-flash or FOP-flash plasmid DNA 
along with a pGL4 renilla luciferase construct, using X-treme gene 9 transfection reagent. Reporter firefly and 
renilla luciferase activity were measured in triplicate 48 hours later on cleared cell lysates using the dual luciferase 
assay system (Promega, Madison, WI, USA).) as instructed by the manufacturer. After normalization of firefly to 
renilla luciferase activity data were represented as the ratio of TOP-flash:FOP-flash activity.
Native gel electrophoresis. Cell lysates were prepared in lysis buffer (10 mM HEPES pH 7.9, 0.5 mM 
EDTA, 12.5 mM MgCl2, 1 mM DTT, 0.05% NP40) containing proteases and phosphatase inhibitors by perform-
ing 6 cycles of freeze/thawing and shearing DNA with a 22G needle. Equal protein amounts from cleared lysates 
after centrifugation at 14000 rpm for 10 min at 4 °C were loaded onto a 5% native gel. After transfer to nitrocellu-
lose identical lanes were separated and each protein separately revealed with appropriate primary and secondary 
antibodies. Proteins were also revealed in the same lanes using sequences of primary and secondary antibodies 
that guarantee no cross-reactivity, stripping the nitrocellulose after each detection and using secondary antibod-
ies conjugated to different fluorochromes. Signals were revealed using Fusion FX (Vilbert-Loumat).
Immunoprecipitation. Cell lysates for immunoprecipitation were prepared as above and incubated with 
anti-V5 conjugated agarose beads (SIGMA) for 3 hrs at 4 °C. After washing, bound proteins were eluted by the 
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addition of excess V5 peptide, subjected to SDS-PAGE and blotted with anti-HDAC1or anti-TCF4 antibody. For 
LEF-1 immunoprecipitation cells were lysed in RIPA buffer and incubated with 5 μg of antibody overnight at 4 °C, 
and then with protein G-sepharose beads. After washing, bound proteins were eluted by boiling in sample buffer 
and analyzed on SDS-PAGE. After transfer to nitrocellulose mouse anti-V5 and HRP-goat anti-mouse antibodies 
were used.
Chromatin immunoprecipitation. ChIP for Histone H3 AcK9 was performed according to Abcam pro-
tocols (Abcam, Cambridge, UK). Briefly 107 cells were cross-linked with 1% folmaldehyde for 10 min. After addi-
tion of 0.125 M glycine and washing in PBS, cells were lysed and the chromatin fraction was sheared to roughly 
600 bp fragments by sonication. About 1/15 of the lysate was stored as input DNA. Immunoprecipitation was 
performed using antibody ab7028 (Abcam) or rabbit immunoglobulins as negative control and herring sperm 
DNA blocked protein A-sepharose beads. Cross-linkage was reversed using proteinase K and DNA purified by 
phenol/chloroform extraction and ethanol precipitation. Quantitative PCR on the immunoprecipitate and on 
input DNA was performed on a ABI Prism 7700 instrument (Applied Biosystems). Primers complementary to 
several regions of the mouse Axin-2 promoter within residues –1731 to + 3268 were designed using Assay Design 
Center ProbeFinder (Roche). Primer sequences are reported in Table S7.
Proximity ligation assay (PLA) and Immunofluorescnce. Proximity ligation assay was performed 
using a Duolink II Fluorescence PLA kit (Olink Bioscience, Uppsala, Sweden) as instructed by the manufac-
turer. Cells were seeded at 70% confluence in 0.2 cm2 dishes, fixed in 4% paraformaldehyde in PIPES buffer for 
13 minutes at RT and permeabilized with 0.3% triton in PBS for 3 minutes. Primary antibodies were used at the 
following dilutions: 1:2000 for mouse anti-V5, rabbit anti V5, monoclonal anti-HA, rabbit anti-HDAC1 Ab7028, 
mouse anti-β -catenin and rabbit anti-β -catenin. Anti-HDAC1 Ab46985 1:100, anti LEF-1 1:400, anti TLE-1and 
anti TLE1,2,3,4 1:100, anti TCF4:1:1000. PLA amplification was labeled with Alexa Fluor 594 (Olink Bioscience, 
Uppsala, Sweden). Slides were counterstained with DAPI, mounted and imaged using the Zeiss Confocal 
Fluorescent Microscope LSM710, with oil immersion objective 63X, NA 1.4. For each channel the pin hole was 
set to 0.9 AU. For each sample the Z-stack was acquired with a line averaging of 2 passages and with a sampling 
in the XYZ according to the optimal Nyquist criteria. Before analysis the Z-stack was converted with maximum 
intensity projection. The resulting images were analyzed using ImageJ software (http://rsbweb.nih.gov/ij/) with 
a script that defines as region of interest (ROI) the DAPI stained nuclei and counts the included PLA fluorescent 
foci (algorithm described in supplemental methods). For statistical analysis fluorescent foci were counted for 
each sample in 5 different fields each containing an average of 8–10 cells. Details can be found in supplemental 
methods.
Chromatin accessibility tests (ChART-PCR). ChART-PCR was performed as previously described with 
slight modifications53. Details can be found in supplemental methods.
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